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PURPOSE: To evaluate long-term use, efficacy and tolerability of transcutaneous
tibial nerve stimulation (TTNS) in the treatment of refractory overactive bladder
(OAB).
METHODS: We performed a prospective observational study and included all
patients treated in a single center for OAB persisting after first-line anticholinergic
treatment, with ≥ 24 months follow-up. The protocol consisted of daily stimulation at
home. The primary outcome was treatment persistence. Amelioration was defined as
an improvement in urinary symptom profile (USP) score.
RESULTS: We assessed 84 consecutive patients. After a mean follow-up of
39.3 months and a mean treatment use of 8.3 months, almost two-thirds of patients
(71.8%) had discontinued TTNS. Treatment continuation was > 12 months for 28
patients (33.3%) and > 18 months for 16 patients (19%). TTNS was successful
following 3 months of treatment in 60 (71%) patients. Mean USP score stayed
significantly lower than baseline until 12 months of treatment, but was not
significant anymore after 18 months. Discontinuation therapy reasons were a lack of
sufficient symptom relief for 59 (70%) patients, compliance difficulty for 5 (6%)
patients and becoming asymptomatic for 6 (8%) patients. No serious adverse events
occurred.
CONCLUSIONS: The present study confirms the utility of TTNS as a treatment
option for patients with resistant OAB. In the long-term use, few patients continued
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